Umpierrez, G.E., Cardona, S., Chachkhiani, D., et al. (2018) A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients with Type 2 Diabetes in Long-Term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial. Journal of the American Medical Directors Association, 19, 399-404.e3.
https://doi.org/10.1016/j.jamda.2017.11.002

has been cited by the following article:

• TITLE: Proposed Libyan Guidelines for the Management of Inpatient Hyperglycemia with Corona Virus-19 (COVID-19) Infection

  AUTHORS: Adela H. Elamami

  KEYWORDS: In-Patient Hyperglycemia, COVID-19, Management, Proposed Guideline, Libya

  JOURNAL NAME: Open Journal of Epidemiology, Vol.11 No.3, July 23, 2021

  ABSTRACT: Serious hyperglycemia is one of the manifestations of COVID-19 infection which increase patient morbidity and mortality especially in patient requiring hospitalization. Consequently, many protocols and algorithms for hospitalized patients with COVID-19 induced hyperglycemia based mainly on recent studies and previous evidence on non-COVID-19 patients were published. Of note nearly all guidelines released by the different COVID-19 committees in Libya don’t include a clear focus on management of in-patient hyperglycemia and maybe this plays a pivotal role in increase our COVID-19 in-hospital mortality. I proposed a simplified approach depending on the released international guidelines to be easily implemented by Libyan health care staff caring about COVID-19 patients and hoping to be accepted by our National Diabetes Committee.